Kinetic analysis of the toxicological effect of tacrine (Cognex®) on human retinal acetylcholinesterase activity

Toxicology

Volumn 147, Issue 1, 2000, Pages 33-39

  Alhomida, Abdullah S ^a   Al Rajhi, Ali A ^b   Kamal, Mohammad A ^a   Al Jafari, Abdulaziz A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING KHALED EYE SPECIALIST HOSPITAL   (Saudi Arabia)

Author keywords

Acetylcholinesterase; Alzheimer's disease; Inhibition; Kinetics; Retina; Tacrine

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITOR; TACRINE;

ALZHEIMER DISEASE; ARTICLE; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; LIVER TOXICITY; MICHAELIS MENTEN KINETICS; PRIORITY JOURNAL; TOXICITY TESTING; VISION;

ACETYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; EYE PROTEINS; HUMANS; KINETICS; NOOTROPIC AGENTS; RETINA; TACRINE;

EID: 0034685887     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-483X(00)00177-3     Document Type: Article

References (28)

1. Adem A., Mohammed A.K., Winblad B. Multiple effects of tetrahyroaminoacridine on the cholinergic system: biochemical and behavioral aspects. J. Neural. Transm. Park. Dis. Dement. Sect. 2:1990;113-128.
2. Al-Jafari A.A. The nature of the inhibition of camel retina acetylcholinesterase (EC 3.1.1.7) activity by tetrahydroaminoacridine. J. Ocul. Pharmacol. Ther. 12:1996;503-514.
3. Al-Jafari A.A., Kamal M.A., Alhomida A.S. Sensitivity of bovine retinal acetylcholinesterase (EC 3.1.1.7) towards tacrine: kinetic characterization. J. Biochem. Mol. Toxicol. 12:1998;245-251.
4. Avery E.E., Baker L.D., Asthana S. Potential role of muscarinic agonists in Alzheimer's disease. Drugs Aging. 11:1997;450-459.
5. Becker R., Moriearty P., Unni L. The second generation of cholinesterase inhibitors: clinical and pharmacological effects. Becker R., Giacobini E. Cholinergic Basis of Alzheimer's disease. 1997;263-296 Brirkhauser, Boston.
6. Berman H.A., Leonard K. Interaction of tetrahydroaminoacridine with acetylcholin-esterase and butyrylcholinesterase. Mol. Pharmacol. 41:1992;412-418.
7. Cohen S.G., Chishti S.B., Bell D.A., Howard S.I., Salih E., Cohen J.B. General occurrence of binding to acetylcholinesterase-substrate complex in noncompetitive inhibition and in inhibition by substrate. Biochim. Biophys. Acta. 1076:1991;112-122.
8. Deutsch J. The cholinergic synapse and the site of memory. Science. 313:1985;7-11.
9. Dixon M. The determination of enzyme inhibitor constant. J. Biochem. 55:1953;170-171.
10. Eagger S., Morant N., Levy R., Sahakian B. Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects. Br. J. Psychol. 160:1992;36-40.
11. Ellman G.L., Courtney K.D., Andres V.J., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
12. Famiglietti Jr E.V. Starburst amicrine cells and cholinergic neurons mirror symmetric ON and OFF amicrine cells of rabbit retina. Brain Res. 261:1983;138-144.
13. Giacobini E. Cholinesterase inhibitors do more than inhibit cholinesterase. Becker R., Giacobini E. Alzheimer's Disease: From Molecular Biology to Therapy. 1997;187-204 Birkhuser, Boston.
14. Hinton D.R., Sadun A.A., Blanks J.C., Miller C.A. Optic-nerve degeneration in Alzheimer's disease. N. Engl. J. Med. 315:1986;485-487.
15. Hodge A.S., Humphrey D.R., Rosenberry T.L. Ambenonium is a rapidly reversible non-covalent inhibitor of acetylcholinesterase, with one of the highest known affinities. Mol. Pharmacol. 41:1992;937-942.
16. Hutchins J.B. Acetylcholine as a neurotransmitter in the vertebrate retina. Exp. Eye Res. 45:1987;1-38.
17. Kasa P., Rakonczay Z., Gulya K. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 52:1997;511-535.
18. Leatherbarrow, R.J., 1992. GraFit, Version 3.0, Erithacus Software Ltd., Staines, UK.
19. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1953;265-275.
20. Masland R.H., Mills J.W. Autoradiographic identification of acetylcholine in the rabbit retina. J. Cell. Biol. 83:1979;159-178.
21. Molly D.W., Guyatt G.H., Wilson D.B., Duke R., Rees L., Singer J. Effect of tetrahydroaminoacridine on cognition, function and behavior in Alzheimer's disease. Can. Med. Assoc. J. 144:1991;29-34.
22. Newhouse P.A., Potter A., Levin E.D. Nicotinic system involvement in Alzheimer's and Parkinson's diseases. Implications for therapeutics. Drugs Aging. 11:1997;206-208.
23. Pourcho R.G., Osman K. Acetylcholinesterase localization in cat retina: a comparison with choline acetyltransferase. Exp. Eye Res. 43:1986;585-594.
24. Ross C.D., Dunning D.D., Juengel L.I., Godfrey D.A. Laminar distribution of choline acetyltransferase and acetylcholinesterase activities in the inner plexiform layer of rat retina. Exp. Eye Res. 465:1985;1091-1099.
25. Segel, I.H., 1975. Behavior and analysis of rapid equilibrium and steady-state enzyme systems. Enzyme Kinetics, New York, John Wiley and Sons, pp. 170-176.
26. Small, D.H., 1989. Acetylcholinesterase: Zymogens of neuropeptide processing enzymes? Neuroscience. 291-299.
27. Soreq H., Zakut H. Human Cholinesterases and Anticholinesterases. 1993;Academic Press, New York.
28. Strenn K., Dal-Bianco P., Weghaupt H., Koch G., Vass C., Gottlob I. Pattern electroretinogram and luminance electroretinogram in Alzheimer's disease. J. Neural. Transm. Supp. 33:1991;73-80.